Novo Nordisk
NVO
A$106.06
Share price
1.16%
Change (1 day)
-51.36%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) Fails to deliver data
Key failure to deliver metrics for Novo Nordisk:
- Last SEC data release: 2025-06-13
- Last 15 days FTD volume: A$9.42 M
- Last 3 months FTD volume: A$55.95 M
- Last year FTD volume: A$55.95 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Novo Nordisk (NVO) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Novo Nordisk (NVO) - since 2013
Volume in USD (price x number of shares), data since 2013Novo Nordisk (NVO) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | A$81.97 M | -66.93% |
| 2024 | A$0.24 B | 179.42% |
| 2023 | A$88.71 M | -11.66% |
| 2022 | A$0.10 B | 125.23% |
| 2021 | A$44.58 M | 70.14% |
| 2020 | A$26.2 M | -57.24% |
| 2019 | A$61.28 M | -22.47% |
| 2018 | A$79.04 M | 3.14% |
| 2017 | A$76.63 M | 5.66% |
| 2016 | A$72.53 M | -28.24% |
| 2015 | A$0.10 B | -51.63% |
| 2014 | A$0.20 B | 598.64% |
| 2013 | A$29.9 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Pfizer PFE | A$27.54 M | A$0.27 B | 🇺🇸 USA |
 Eli Lilly LLY | A$34.52 M | A$0.21 B | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$12.67 M | A$0.27 B | 🇺🇸 USA |
 Sanofi SNY | A$28.45 M | A$44.01 M | 🇫🇷 France |